IRVING, Texas , Nov. 21, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the selection of 15 physician-scientists to participate in its 2025/2026 Caris Precision Oncology Alliance (Caris POA) Fellows Forum. This competitive two-year program provides early-career oncologists with hands-on training, mentorship and access to real-world molecular data, empowering them to develop and test clinically meaningful precision medicine hypotheses.

To be considered for the program, applicants must be physician-scientists in their first or second year of oncology fellowship at one of Caris' POA institutions. Caris POA fellows were chosen through a competitive review process eval

See Full Page